Black Diamond Therapeutics

BDTX

Market cap $95.7M

BDTX Hedge Fund Activity: Q1 2026 in Review

104 of the 8,134 institutional investors tracked by Wall St. Rank reported a position in Black Diamond Therapeutics (BDTX) for Q1 2026, worth a combined $82M — down 11% from $92M a quarter earlier.

Buyers outnumbered sellers: 23 funds opened new BDTX positions and 21 closed out — a net gain of 2 holders — while 30 added to existing stakes and 34 trimmed.

The largest buyer was Acadian Asset Management, adding an estimated $1.71M. The largest seller was Siren LLC, exiting entirely with an estimated $2.54M sold.

• 104 institutional investors held Black Diamond Therapeutics (BDTX) as of Q1 2026, unchanged from Q4 2025.
• Funds reported $82M of Black Diamond Therapeutics stock for Q1 2026, down 11% quarter-over-quarter.
• 23 funds opened new Black Diamond Therapeutics positions in Q1 2026 and 21 closed out, a net change of +2 holders.
• The largest Black Diamond Therapeutics buyer in Q1 2026 was Acadian Asset Management, an estimated $1.71M added.
• The largest Black Diamond Therapeutics seller in Q1 2026 was Siren LLC, an estimated $2.54M sold.

Based on aggregated 13F filings for Q1 2026.